BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 9848296)

  • 21. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of two gonadotropin-releasing hormone (GnRH) analogues (leuprolide and buserelin) in short and long protocols for assisted reproduction techniques.
    Tarlatzis BC; Grimbizis G; Pournaropoulos F; Bontis J; Lagos S; Pados G; Mantalenakis S
    J Assist Reprod Genet; 1994 Feb; 11(2):85-91. PubMed ID: 7819707
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pituitary suppression in ultrasound-monitored frozen embryo replacement cycles. A randomised study.
    El-Toukhy T; Taylor A; Khalaf Y; Al-Darazi K; Rowell P; Seed P; Braude P
    Hum Reprod; 2004 Apr; 19(4):874-9. PubMed ID: 15016780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GnRH analogues for contraception.
    Fraser HM
    Br Med Bull; 1993 Jan; 49(1):62-72. PubMed ID: 8324616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative study on the pregnancy outcomes of in vitro fertilization-embryo transfer between long-acting gonadotropin-releasing hormone agonist combined with transvaginal ultrasound-guided cyst aspiration and long-acting gonadotropin-releasing hormone agonist alone.
    Guo YH; Lu N; Zhang Y; Su YC; Wang Y; Zhang YL; Sun YP
    Contemp Clin Trials; 2012 Nov; 33(6):1206-10. PubMed ID: 22820320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective randomized comparison of routine buserelin acetate and a decreasing dosage of nafarelin acetate with a low-dose gonadotropin-releasing hormone agonist protocol for in vitro fertilization and intracytoplasmic sperm injection.
    Takeuchi S; Minoura H; Shibahara T; Tsuiki Y; Noritaka F; Toyoda N
    Fertil Steril; 2001 Sep; 76(3):532-7. PubMed ID: 11532477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective randomized single-blind comparative trial of nafarelin acetate with buserelin in long-protocol gonadotrophin-releasing hormone analogue controlled in-vitro fertilization cycles.
    Lockwood GM; Pinkerton SM; Barlow DH
    Hum Reprod; 1995 Feb; 10(2):293-8. PubMed ID: 7769051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of baseline cysts at the time of administration of gonadotropin-releasing hormone analog for in vitro fertilization.
    Zeyneloglu HB; Isik AZ; Kara S; Senöz S; Ozcan U; Gökmen O
    Int J Fertil Womens Med; 1998; 43(6):300-5. PubMed ID: 9920539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The long protocol of administration of gonadotropin-releasing hormone agonist is superior to the short protocol for ovarian stimulation for in vitro fertilization.
    Tan SL; Kingsland C; Campbell S; Mills C; Bradfield J; Alexander N; Yovich J; Jacobs HS
    Fertil Steril; 1992 Apr; 57(4):810-4. PubMed ID: 1555692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Administration of progestogens to hasten pituitary desensitization after the use of gonadotropin-releasing hormone agonist in in vitro fertilization--a prospective randomized study.
    Shaker AG; Pittrof R; Zaidi J; Bekir J; Kyei-Mensah A; Tan SL
    Fertil Steril; 1995 Oct; 64(4):791-5. PubMed ID: 7672152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early pituitary desensitization and ovarian suppression with leuprolide acetate is associated with in vitro fertilization-embryo transfer success.
    Seifer DB; Thornton KL; DeCherney AH; Lavy G
    Fertil Steril; 1991 Sep; 56(3):500-4. PubMed ID: 1909977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The induction of amenorrhoea.
    Hipkin LJ
    J R Army Med Corps; 1992 Feb; 138(1):15-8. PubMed ID: 1533675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Progress in the contraceptive use of the LH-RH agonist buserelin: intermittent medication with gestagen-induced withdrawal bleeding].
    Hardt W; Schmidt-Gollwitzer K; Nevinny-Stickel J; Schmidt-Gollwitzer M
    Geburtshilfe Frauenheilkd; 1982 Dec; 42(12):874-7. PubMed ID: 6819180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM; Nashan D; Hubert W; Nieschlag E
    J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of pretreatment with oral contraceptives and progestins on IVF outcomes in women with polycystic ovary syndrome.
    Wei D; Shi Y; Li J; Wang Z; Zhang L; Sun Y; Zhou H; Xu Y; Wu C; Liu L; Wu Q; Zhuang L; Du Y; Li W; Zhang H; Legro RS; Chen ZJ
    Hum Reprod; 2017 Feb; 32(2):354-361. PubMed ID: 27999118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum gonadotropin and ovarian steroid levels in women during administration of a norethindrone-ethinylestradiol triphasic oral contraceptive.
    Ling WY; Johnston DW; Lea RH; Bent AE; Scott JZ; Toews MR
    Contraception; 1985 Oct; 32(4):367-75. PubMed ID: 3935373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the effects of contraceptive steroid formulations containing two doses of estrogen on pituitary function.
    Scott JZ; Kletzky OA; Brenner PF; Mishell DR
    Fertil Steril; 1978 Aug; 30(2):141-5. PubMed ID: 98356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis.
    Vercellini P; Trespidi L; Colombo A; Vendola N; Marchini M; Crosignani PG
    Fertil Steril; 1993 Jul; 60(1):75-9. PubMed ID: 8513962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Do the suppression criteria in GnRH-a cycles predict in vitro fertilization outcome?
    Senöz S; Gülekli B; Turhan NO; Ozakşit G; Odabaşi AR; Oral H; Ozcan U; Gökmen O
    Gynecol Endocrinol; 1995 Jun; 9(2):91-6. PubMed ID: 7502695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.